• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Vaccines, Blood & Biologics

  • Print
  • Share
  • E-mail
?
-

Resources for You

Vaccinia Immune Globulin Intravenous (Human)

STN: BL 125109
Proper Name: Vaccinia Immune Globulin Intravenous (Human)
Tradename: None
Manufacturer: Cangene Corp, License #1201
Indications:

  • treatment and/or modification of the following conditions, which are complications resulting from smallpox vaccination
    • Eczema vaccinatum
    • Progressive vaccinia
    • Severe generalized vaccinia
    • Vaccinia infections in individuals who have skin conditions such as burns, impetigo, varicella-zoster, or poison ivy; or in individuals who have eczematous skin lesions because of either the activity or extensiveness of such lesions
    • Aberrant infections induced by vaccinia virus that include its accidental implantation in eyes (except in cases of isolated keratitis), mouth, or other areas where vaccinia infection would constitute a special hazard.
-

Product Information

-
-

Related Information

  • FDA Online Label Repository
    Search this database for drug labeling and other information. The content has not been altered or verified by the FDA and may not be the labeling on currently distributed products or identical to the labeling that is approved.
-
 

Contact FDA

(800) 835-4709
(240) 402-8010
Consumer Affairs Branch (CBER)

Division of Communication and Consumer Affairs

Office of Communication, Outreach and Development

Food and Drug Administration

10903 New Hampshire Avenue

Building 71 Room 3103

Silver Spring, MD 20993-0002